Talis Biomedical Corp Stock Performance
| TLIS Stock | USD 1.60 0.00 0.00% |
Talis Biomedical has a performance score of 3 on a scale of 0 to 100. The entity has a beta of -0.31, which indicates possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Talis Biomedical are expected to decrease at a much lower rate. During the bear market, Talis Biomedical is likely to outperform the market. Talis Biomedical Corp right now has a risk of 3.71%. Please validate Talis Biomedical information ratio and kurtosis , to decide if Talis Biomedical will be following its existing price patterns.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Talis Biomedical Corp are ranked lower than 3 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively fragile forward indicators, Talis Biomedical may actually be approaching a critical reversion point that can send shares even higher in January 2026. ...more
Talis |
Talis Biomedical Relative Risk vs. Return Landscape
If you would invest 150.00 in Talis Biomedical Corp on September 9, 2025 and sell it today you would earn a total of 10.00 from holding Talis Biomedical Corp or generate 6.67% return on investment over 90 days. Talis Biomedical Corp is currently generating 0.1644% in daily expected returns and assumes 3.7143% risk (volatility on return distribution) over the 90 days horizon. In different words, 33% of pink sheets are less volatile than Talis, and 97% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Talis Biomedical Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Talis Biomedical's investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Talis Biomedical Corp, and traders can use it to determine the average amount a Talis Biomedical's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0443
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | TLIS | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Based on monthly moving average Talis Biomedical is performing at about 3% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Talis Biomedical by adding it to a well-diversified portfolio.
Talis Biomedical Fundamentals Growth
Talis Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Talis Biomedical, and Talis Biomedical fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Talis Pink Sheet performance.
| Return On Equity | -0.7 | |||
| Return On Asset | -0.3 | |||
| Operating Margin | (113.60) % | |||
| Current Valuation | (38.24 M) | |||
| Shares Outstanding | 1.82 M | |||
| Price To Book | 0.06 X | |||
| Price To Sales | 19.57 X | |||
| Revenue | 412 K | |||
| EBITDA | (60.7 M) | |||
| Cash And Equivalents | 165.37 M | |||
| Cash Per Share | 6.21 X | |||
| Total Debt | 19.67 M | |||
| Debt To Equity | 0.19 % | |||
| Book Value Per Share | 26.68 X | |||
| Cash Flow From Operations | (53.24 M) | |||
| Earnings Per Share | (28.02) X | |||
| Total Asset | 98.34 M | |||
| Retained Earnings | (539.96 M) | |||
About Talis Biomedical Performance
Assessing Talis Biomedical's fundamental ratios provides investors with valuable insights into Talis Biomedical's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Talis Biomedical is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
Talis Biomedical Corporation operates as a molecular diagnostic company. Talis Biomedical Corporation was incorporated in 2013 and is headquartered in Menlo Park, California. Talis Biomedical operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 242 people.Things to note about Talis Biomedical Corp performance evaluation
Checking the ongoing alerts about Talis Biomedical for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Talis Biomedical Corp help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Talis Biomedical may become a speculative penny stock | |
| Talis Biomedical had very high historical volatility over the last 90 days | |
| Talis Biomedical has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 412 K. Net Loss for the year was (62.01 M) with loss before overhead, payroll, taxes, and interest of (149.4 M). | |
| Talis Biomedical Corp currently holds about 165.37 M in cash with (53.24 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.21, which can makes it an attractive takeover target, given it will continue generating positive cash flow. |
- Analyzing Talis Biomedical's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Talis Biomedical's stock is overvalued or undervalued compared to its peers.
- Examining Talis Biomedical's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Talis Biomedical's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Talis Biomedical's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Talis Biomedical's pink sheet. These opinions can provide insight into Talis Biomedical's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Talis Pink Sheet Analysis
When running Talis Biomedical's price analysis, check to measure Talis Biomedical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Talis Biomedical is operating at the current time. Most of Talis Biomedical's value examination focuses on studying past and present price action to predict the probability of Talis Biomedical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Talis Biomedical's price. Additionally, you may evaluate how the addition of Talis Biomedical to your portfolios can decrease your overall portfolio volatility.